XPH(SZ:300147)2022-12-08 03:04Group 1: Company Strategy and Development - The company has established traditional Chinese medicine planting bases in Ningxia Longde and Yunnan Diqing, focusing on the upstream layout of Chinese medicine resources [2] - The product layout includes traditional slices, ultra-fine slices, and the finest powder, while the formula granules are currently lacking and will be applied for qualification once national policies allow [3] - The main distribution channels for Chinese medicine slices are hospitals, followed by pharmacies, pharmaceutical factories, and trade exports [3] Group 2: Specific Projects and Collaborations - The specific T cell therapy project aims to develop new biological drugs for tumors, infectious diseases, and autoimmune diseases, with a focus on high-affinity TCR patents [4] - The company collaborates with 458 hospitals to conduct clinical research on specific T cell adoptive immunotherapy for solid tumors, primarily targeting liver cancer caused by hepatitis B and non-small cell lung cancer [4] - The first phase of patient treatment has been completed, and data is currently being organized [4] Group 3: Mergers and Acquisitions - Mergers and acquisitions are a strategic direction for the company, focusing on companies with complementary products, technologies, and channels [5] - The management will cautiously evaluate risks and benefits before proceeding with any mergers or acquisitions [5] Group 4: Employee Stock Ownership Plan - As of June 18, 2015, the "CITIC Securities Xiangxue Wealth No. 1 Collective Asset Management Plan" purchased a total of 7,810,147 shares, accounting for 1.18% of the company's total share capital, with an average purchase price of 30.84 yuan [5] - The total amount spent on the stock purchase was 240,859,050.86 yuan, and the lock-up period for the first phase of the employee stock ownership plan is from June 19, 2015, to June 18, 2016 [5]